Project Grant HT94252510488

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program will support $574,427 in research to investigate the role of amino acid metabolism in regulating brain tumor growth and immune function. The 5-year project, awarded on September 20, 2024 to the University of Pittsburgh, will utilize patient-derived cultures, organoids, and...

The National Institute on Aging (NIA) awarded a $810,596 Project Grant under the Aging Research program (CFDA 93.866) to New York University (NYU) to develop a novel chimeric antigen receptor (CAR) macrophage (MI) therapy for Alzheimer's disease (AD). The objectives are to create "off-the-shelf" human induced pluripotent stem cell-derived MIs that can be genetically programmed to target and clear amyloid-beta deposits, a key pathological hallmark of AD. The 2-year award period runs...

This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $374,000.00 to the University of California, Los Angeles (UCLA) to develop and evaluate a novel hematopoietic stem cell-based chimeric antigen receptor (CAR) macrophage therapy for Alzheimer's disease (AD). The key objectives are to: 1) Optimize an AB-targeting CAR-macrophage (CAR-M) therapy for in vitro efficacy against AB aggregates and reducing neuroinflammation, and 2) Investigate the safety...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to develop an encapsulated cell-based oncolytic virus therapy for brain tumors, specifically glioblastoma (GBM). The $420,251 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will fund the development and testing of mesenchymal stem...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas M.D. Anderson Cancer Center provides $432,134.00 in funding to establish a radiotheranostic approach for treating glioblastoma (GBM), a highly aggressive brain cancer, by targeting the IL13RA2 protein expressed on cancer cells. The research aims to develop human monoclonal antibodies that bind to IL13RA2 with high affinity and specificity, and evaluate the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct a Phase I clinical trial evaluating the safety and feasibility of CARV3.TEAM-E cells for the treatment of primary or recurrent glioblastoma (GBM), a deadly brain tumor. The CARV3.TEAM-E cells are genetically engineered chimeric antigen receptor (CAR) T cells that target the...

This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $417,858 to Brigham & Women's Hospital in Boston, MA to develop a platform of mesenchymal stem cell (MSC) therapies that release bispecific T cell engager (BiTE) molecules targeting multiple antigens overexpressed in glioblastoma brain tumors. The key products and services to be delivered under this 5-year grant include: Developing and extensively testing the therapeutic...